Thrombin

Ximelagatran, oral direct thrombin inhibitor, transforms to active melagatran in body.

NQ301, an antithrombotic agent, inhibits collagen-challenged rabbit platelet aggregation (IC50: 10 mg/mL).

Cycloolivil (Isoolivil) is a natural polyphenolic compound with a significant radical scavenging activity present in olive trees.

Dabigatran (BIBR 953ZW), a thrombin inhibitor, prevents thrombus formation, reducing stroke and embolism risk in nonvalvular atrial fibrillation patients.

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

Argatroban Monohydrate is a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.

Argatroban (MCI-9038), a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.

Idarucizumab, a humanized monoclonal antibody fragment, serves as the first reversal agent for direct oral anticoagulants (DOACs).

Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets thrombin. It binds to exosite 1 of thrombin, inhibiting substrate binding without affecting its catalytic activity. For isotype control, refer to HumanIgG1kappa, Isotype Control.

TPO agonist 1, Thrombopoietin (TPO) mimetic, promotes platelet/megakaryocyte production, for thrombocytopenia research.

Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.

Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.

Efegatran sulfate (LY294468 sulfate) is a potent thrombin inhibitor used in the treatment of thrombotic disorders.

YD-3 is a PAR4 antagonist that significantly inhibits thrombin-induced platelet aggregation in rabbits (IC(50)=28.3 microM). In addition, YD-3 suppresses thrombin-induced proliferation of vascular smooth muscle cells (VSMCs) and reduces neointimal thickening after balloon injury. Through Ras- and ERK1/2-mediated signaling pathways, YD-3 impedes thrombin-driven VSMC proliferation. When analyzed with Western blot, YD-3 primarily inhibits thrombin-induced expression of vascular endothelial growth factor receptor 2 (Flk-1) without affecting extracellular signal-regulated kinase 1/2 phosphorylation. YD-3 could potentially have value in elucidating the pathophysiology of thrombin-induced angiogenesis.

Flovagatran (TGN 255) is a potent, and selective inhibitor of thrombin and parenteral direct factor II.Flovagatran is used to study venous thromboembolism.

OM-189 is a selective inhibitor of synthetic thrombin.

Thrombin inhibitor 13 (Compound 13a) acts as a covalent reversible inhibitor of thrombin (thrombin, FIIa) with an IC50 of 0.7 nM. This compound prolongs activated partial thromboplastin time (aPTT) and prothrombin time (PT), demonstrating both antithrombotic and anticoagulant properties.

Melagatran is an orally available, direct synthetic thrombin inhibitor that does not require endogenous cofactors other than thrombin.Cost-effective and quality-assured.

SCH79797 dihydrochloride is a PAR1 antagonist with IC50 70 nM, Ki 35 nM, antiproliferative, and pro-apoptotic properties.

Thrombin inhibitor 1 is a potent inhibitor of thrombin (Ki: 0.66 nM, 2xaPTT=0.43 μM).